J&J's impending split; And the next FDA commish is...; Aduhelm back in spotlight; #AHA21; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
As we mark the 40th edition of this Saturday recap, I’d like to spend a moment marveling at just how much Endpoints News has grown in the past year. We used to just have two daily reports. But we now send out weekly email newsletters dedicated to pharma marketing (Endpoints MarketingRx), regulatory news (Endpoints FDA+) and manufacturing (Endpoints Manufacturing). Want to get them in your inbox? You can customize your list of subscriptions in the reader profile.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.